Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience

Manish Maladkar; Chitra Tekchandani; Urja Dave

doi:doi:10.11648/j.jgo.20150303.12

| Peer-Reviewed

Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience

Manish Maladkar, Chitra Tekchandani, Urja Dave

Published in Journal of Gynecology and Obstetrics (Volume 3, Issue 3)

Received: 17 February 2015 Accepted: 5 March 2015 Published: 23 April 2015

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Vaginal infections are among the most frequent disorders affecting a woman and comprise over 95% of lower female genital tract infections. Seventy five percent of the women world-wide suffer from vaginosis resulting from bacterial, fungal and protozoal infections. Several studies have shown that mixed vaginal infections occur frequently and hence, in co-infection, each pathogen requires specific therapy for complete eradication of concurrent manifestations. Materials and Methods: A multicenter, prospective, open-label, non-comparative clinical study was carried out in 495 patients with mixed vaginosis of bacterial, fungal and protozoal origin. A fixed dose combination of Clindamycin 100 mg, Clotrimazole 100 mg and Tinidazole 100 mg was administered intravaginally for 7 consecutive nights. Results: Treatment led to significant reduction in various symptoms of vaginal infection within 3 days of treatment initiation. On day 7 of treatment, 98.6% patients had normal and odourless vaginal discharge, the mean vaginal burning and irritation score declined by 99.2% and 99.3% respectively. Also, there was remission of vulvar, cervical and vaginal erythema in more than 98% of patients. Physicians and patients rated the treatment efficacy as good to very good improvement and tolerability to the treatment was regarded as good to excellent. No serious adverse events were reported. Conclusion: The present study demonstrates that fixed dose combination of Clindamycin, Clotrimazole and Tinidazole is effective and well tolerated in the treatment of mixed vaginosis due to bacterial, fungal and protozoal infection.

Published in	Journal of Gynecology and Obstetrics (Volume 3, Issue 3)
DOI	10.11648/j.jgo.20150303.12
Page(s)	49-54
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2015. Published by Science Publishing Group

Keywords

Clindamycin, Clotrimazole, Tinidazole, Vaginosis, Candidiasis, Trichomoniasis

References

[1]	Marion KO, Timothy LC. Management of Vaginitis. American Family Physician. 2004; 70: 2125-32.
[2]	Fabio P, Aroldo C, Geraldo D, Lara L, Luis B, Alvaro P. Efficacy and tolerance of metronidazole and miconazole nitrate in treatment of vaginitis. International Journal of Gynecology and Obstetrics. 2008; 102: 287–292.
[3]	Linda OE. Acute Vulvovaginitis. New England Journal of Medicine. 2006; 355: 1244-52.
[4]	Divya AP, Nancy MB, Kathryn MC. Reproductive Tract Infections. Centers for Disease Control and Prevention. 2003; module 3: 1-83.
[5]	Tahniat SS, Paula KB. Vaginitis in adolescents. Adolescent medicine clinics. 2004; 15: 235-251.
[6]	Jyoti T, Alka K, Nutan A, Sreenivas V. Aetiology & risk factors of recurrent vaginitis & its association with various contraceptive methods. Indian Journal of Medical Research. 2010; 131: 83-87.
[7]	Katz, Lentz, Lobo, Gershenson. Comprehensive Gynecology, 5th ed., 2007.
[8]	Prashini M, Cathy C, Willem AS. Interrelationships among Human Immunodeficiency Virus Type 1 Infection, Bacterial Vaginosis, Trichomoniasis, and the Presence of Yeasts. The Journal of Infectious Diseases. 2002; 185: 69-73.
[9]	Líbalová Z , Cepický P, Malina J, Stanslický K, Kuzelová M, Medalová Z, et al. Vulvovaginitis. Occurrence and importance of mixed and unclassifiable Pictures. Ceská Gynekologie. 2007;72:32-7.
[10]	Karaca M , Bayram A, Kocoglu ME, Gocmen A, Eksi F. Comparison of clinical diagnosis and microbiological test results in vaginal infections. Clinical and Experimental Obstetrics and Gynecology. 2005; 32: 172-4.
[11]	Cepický P, Malina J, Líbalová Z, Kuzelová M. Mixed" and "miscellaneous" vulvovaginitis: diagnostics and therapy of vaginal administration of nystatin and nifuratel. Ceská Gynekologie. 2005;70:232-7.
[12]	Reid G, Bruce A W. Urogenital infections in women: can probiotics help? Postgraduate Medical Journal. 2003;79:428-32.
[13]	Sarah R, Natasha A, Gillian S, Andrew W. Practical management of recurrent vulvovaginal candidiasis. Trends in Urology Gynaecology & Sexual Health. 2009; 14: 18-32.
[14]	E O¨zyurt, MB Toykuliyeva, IL Danilyans, O Morton, G Baktir. Efficacy of 7-day treatment with metronidazole + miconazole (Neo-Penotran) a triple-active pessary for the treatment of single and mixed vaginal infections. International Journal of Gynecology & Obstetrics. 2001; 74: 35-43.
[15]	Nagaraja P. Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian Journal of Medical Microbiology. 2008; 26:155-7.
[16]	Tomusiak A, Strus M, Heczko PB. Antibiotic resistance of Gardnerella vaginalis isolated from cases of bacterial vaginosis. Ginekologia Polska. 2011;82:900-4.
[17]	Kimberly A. Workowski MD, Stuart M B. Sexually Transmitted Diseases Treatment Guidelines. Centers for Disease Control and Prevention. 2006; 55: 1-94.
[18]	Sheila JA, Rodrigo VL, Zahir T, Elias S, Maria LG, Maria AH et al. Frequency of Trichomonas vaginalis, Candida sp and Gardnerella vaginalis in cervical-vaginal smears in four different decades. Sao Paulo Medical Journal.2001; 119: 200-5.
[19]	Jacques P, François S, Nzambi K, Thomas AP, Soumaila D, Sylvie D et al. The syndromic management of vaginal discharge using single-dose treatments: a randomized controlled trial in West Africa. Bull World Health Organ. 2006; 84: 729–738.
[20]	Kimberly A. Workowski MD, Stuart M B. Sexually Transmitted Diseases Treatment Guidelines. Centers for Disease Control and Prevention. 2010; 59: 1-110.
[21]	Anjali Aggarwal, R. Michael Shier. Recalcitrant Trichomonas Vaginalis Infections Successfully Treated With Vaginal Acidification. Journal of Obstetrics and Gynaecology Canada . 2008; 30:55–58.
[22]	J. D. Sobel, P. Nyirjesy, William Brown. Tinidazole Therapy for Metronidazole-Resistant Vaginal Trichomoniasis. Clinical Infectious Diseases. 2001; 33:1341–6.

Cite This Article

Plain Text BibTeX RIS

APA Style

Manish Maladkar, Chitra Tekchandani, Urja Dave. (2015). Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience. Journal of Gynecology and Obstetrics, 3(3), 49-54. https://doi.org/10.11648/j.jgo.20150303.12

Copy | Download

ACS Style

Manish Maladkar; Chitra Tekchandani; Urja Dave. Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience. J. Gynecol. Obstet. 2015, 3(3), 49-54. doi: 10.11648/j.jgo.20150303.12

Copy | Download

AMA Style

Manish Maladkar, Chitra Tekchandani, Urja Dave. Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience. J Gynecol Obstet. 2015;3(3):49-54. doi: 10.11648/j.jgo.20150303.12

Copy | Download

@article{10.11648/j.jgo.20150303.12,
  author = {Manish Maladkar and Chitra Tekchandani and Urja Dave},
  title = {Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience},
  journal = {Journal of Gynecology and Obstetrics},
  volume = {3},
  number = {3},
  pages = {49-54},
  doi = {10.11648/j.jgo.20150303.12},
  url = {https://doi.org/10.11648/j.jgo.20150303.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20150303.12},
  abstract = {Background: Vaginal infections are among the most frequent disorders affecting a woman and comprise over 95% of lower female genital tract infections. Seventy five percent of the women world-wide suffer from vaginosis resulting from bacterial, fungal and protozoal infections. Several studies have shown that mixed vaginal infections occur frequently and hence, in co-infection, each pathogen requires specific therapy for complete eradication of concurrent manifestations. Materials and Methods: A multicenter, prospective, open-label, non-comparative clinical study was carried out in 495 patients with mixed vaginosis of bacterial, fungal and protozoal origin. A fixed dose combination of Clindamycin 100 mg, Clotrimazole 100 mg and Tinidazole 100 mg was administered intravaginally for 7 consecutive nights. Results: Treatment led to significant reduction in various symptoms of vaginal infection within 3 days of treatment initiation. On day 7 of treatment, 98.6% patients had normal and odourless vaginal discharge, the mean vaginal burning and irritation score declined by 99.2% and 99.3% respectively. Also, there was remission of vulvar, cervical and vaginal erythema in more than 98% of patients. Physicians and patients rated the treatment efficacy as good to very good improvement and tolerability to the treatment was regarded as good to excellent. No serious adverse events were reported. Conclusion: The present study demonstrates that fixed dose combination of Clindamycin, Clotrimazole and Tinidazole is effective and well tolerated in the treatment of mixed vaginosis due to bacterial, fungal and protozoal infection.},
 year = {2015}
}

Copy | Download

TY - JOUR
T1 - Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience
AU - Manish Maladkar
AU - Chitra Tekchandani
AU - Urja Dave
Y1 - 2015/04/23
PY - 2015
N1 - https://doi.org/10.11648/j.jgo.20150303.12
DO - 10.11648/j.jgo.20150303.12
T2 - Journal of Gynecology and Obstetrics
JF - Journal of Gynecology and Obstetrics
JO - Journal of Gynecology and Obstetrics
SP - 49
EP - 54
PB - Science Publishing Group
SN - 2376-7820
UR - https://doi.org/10.11648/j.jgo.20150303.12
AB - Background: Vaginal infections are among the most frequent disorders affecting a woman and comprise over 95% of lower female genital tract infections. Seventy five percent of the women world-wide suffer from vaginosis resulting from bacterial, fungal and protozoal infections. Several studies have shown that mixed vaginal infections occur frequently and hence, in co-infection, each pathogen requires specific therapy for complete eradication of concurrent manifestations. Materials and Methods: A multicenter, prospective, open-label, non-comparative clinical study was carried out in 495 patients with mixed vaginosis of bacterial, fungal and protozoal origin. A fixed dose combination of Clindamycin 100 mg, Clotrimazole 100 mg and Tinidazole 100 mg was administered intravaginally for 7 consecutive nights. Results: Treatment led to significant reduction in various symptoms of vaginal infection within 3 days of treatment initiation. On day 7 of treatment, 98.6% patients had normal and odourless vaginal discharge, the mean vaginal burning and irritation score declined by 99.2% and 99.3% respectively. Also, there was remission of vulvar, cervical and vaginal erythema in more than 98% of patients. Physicians and patients rated the treatment efficacy as good to very good improvement and tolerability to the treatment was regarded as good to excellent. No serious adverse events were reported. Conclusion: The present study demonstrates that fixed dose combination of Clindamycin, Clotrimazole and Tinidazole is effective and well tolerated in the treatment of mixed vaginosis due to bacterial, fungal and protozoal infection.
VL - 3
IS - 3
ER -

Copy | Download

Author Information

Manish Maladkar

Aristo Pharmaceuticals Pvt. Ltd., 23-A Shah Industrial Estate, Andheri, Mumbai, India
Chitra Tekchandani

Aristo Pharmaceuticals Pvt. Ltd., 23-A Shah Industrial Estate, Andheri, Mumbai, India
Urja Dave

Aristo Pharmaceuticals Pvt. Ltd., 23-A Shah Industrial Estate, Andheri, Mumbai, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Manish Maladkar, Chitra Tekchandani, Urja Dave. (2015). Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience. Journal of Gynecology and Obstetrics, 3(3), 49-54. https://doi.org/10.11648/j.jgo.20150303.12

Copy | Download

ACS Style

Manish Maladkar; Chitra Tekchandani; Urja Dave. Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience. J. Gynecol. Obstet. 2015, 3(3), 49-54. doi: 10.11648/j.jgo.20150303.12

Copy | Download

AMA Style

Manish Maladkar, Chitra Tekchandani, Urja Dave. Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience. J Gynecol Obstet. 2015;3(3):49-54. doi: 10.11648/j.jgo.20150303.12

Copy | Download

@article{10.11648/j.jgo.20150303.12,
  author = {Manish Maladkar and Chitra Tekchandani and Urja Dave},
  title = {Clindamycin, Clotrimazole and Tinidazole in Mixed Vaginosis- A “Real World” Clinical Experience},
  journal = {Journal of Gynecology and Obstetrics},
  volume = {3},
  number = {3},
  pages = {49-54},
  doi = {10.11648/j.jgo.20150303.12},
  url = {https://doi.org/10.11648/j.jgo.20150303.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20150303.12},
  abstract = {Background: Vaginal infections are among the most frequent disorders affecting a woman and comprise over 95% of lower female genital tract infections. Seventy five percent of the women world-wide suffer from vaginosis resulting from bacterial, fungal and protozoal infections. Several studies have shown that mixed vaginal infections occur frequently and hence, in co-infection, each pathogen requires specific therapy for complete eradication of concurrent manifestations. Materials and Methods: A multicenter, prospective, open-label, non-comparative clinical study was carried out in 495 patients with mixed vaginosis of bacterial, fungal and protozoal origin. A fixed dose combination of Clindamycin 100 mg, Clotrimazole 100 mg and Tinidazole 100 mg was administered intravaginally for 7 consecutive nights. Results: Treatment led to significant reduction in various symptoms of vaginal infection within 3 days of treatment initiation. On day 7 of treatment, 98.6% patients had normal and odourless vaginal discharge, the mean vaginal burning and irritation score declined by 99.2% and 99.3% respectively. Also, there was remission of vulvar, cervical and vaginal erythema in more than 98% of patients. Physicians and patients rated the treatment efficacy as good to very good improvement and tolerability to the treatment was regarded as good to excellent. No serious adverse events were reported. Conclusion: The present study demonstrates that fixed dose combination of Clindamycin, Clotrimazole and Tinidazole is effective and well tolerated in the treatment of mixed vaginosis due to bacterial, fungal and protozoal infection.},
 year = {2015}
}

Copy | Download